INHIBRX BIOSCIENCES, INC. Share-based Payment Arrangement, Expense
INHIBRX BIOSCIENCES, INC. (INBX) had Share-based Payment Arrangement, Expense of $1.80 million as of 2024-05-30, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Compensation Related Costs
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-03-19
- 2024-05-30: Share-based Payment Arrangement, Expense $1.80M.
| Period end | Share-based Payment Arrangement, Expense |
|---|---|
| 2024-05-30 | $1.80M 10-K · filed 2026-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |